**Association Between MASLD and Increased Risk of Serious Bacterial Infections Requiring Hospital Admission: A Meta-Analysis**

Alessandro Mantovani1, Riccardo Morandin1, Veronica Fiorio1, Maria Giovanna Lando1, Alberto Gaviraghi2, Leonardo Motta2, Federico Gobbi2,3, Herbert Tilg4, Christopher D. Byrne5, Giovanni Targher6,7

1Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Verona, Verona, Italy

2Department of Infectious Tropical Diseases and Microbiology, IRCCS Sacro Cuore - Don Calabria Hospital, Negrar di Valpolicella, Italy

3Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

4Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology and Metabolism, Medical University Innsbruck, Innsbruck, Austria

5National Institute for Health and Care Research, Southampton Biomedical Research Centre, University Hospital Southampton and University of Southampton, Southampton, UK

6Department of Medicine, University of Verona, Italy

7Metabolic Diseases Research Unit, IRCCS Sacro Cuore - Don Calabria Hospital, Negrar di Valpolicella, Italy

**Word count:** Abstract 249; Text 3,993 (*excluding* title page, references, and figure legends); n. 1 **Table**; n. 3 **Figures** + **Online-only Supplementary Material** (n. 1 **Supplementary Table**; n. 9 **Supplementary Figures**;n. 2 **Supplementary Documents**).

**Address for correspondence:**

Prof. Giovanni Targher, MD

Metabolic Diseases Research Unit  
IRCCS Sacro Cuore - Don Calabria Hospital

Viale Luigi Rizzardi, 4

37024 Negrar di Valpolicella (VR), Italy

E-mail: [giovanni.targher@univr.it](mailto:giovanni.targher@univr.it)

**ABSTRACT**

**Background**: Previous studies have reported an association between metabolic dysfunction-associated steatotic liver disease (MASLD) and the risk of serious bacterial infections. However, the magnitude of the risk and whether this risk varies with the severity of MASLD remains uncertain. We performed a meta-analysis of observational studies to quantify the association between MASLD and serious bacterial infections requiring hospital admission.

**Methods**: We systematically searched PubMed, Scopus, Web of Science, and Embase from database inception to April 1, 2024, using predefined keywords to identify studies examining the risk of serious bacterial infections amongst individuals with and without MASLD. MASLD was diagnosed using biopsy, imaging, or International Classification of Diseases codes. Meta-analysis was performed using random-effects modelling.

**Results**: We identified six cross-sectional and two prospective studies with aggregate data on ~26.6 million individuals. MASLD was significantly associated with higher odds of serious bacterial infections (pooled random-effects odds ratio 1.93, 95%CI 1.44-2.58; *I2*=93%). Meta-analysis of prospective studies showed that MAFLD was associated with an increased risk of developing severe bacterial infections (pooled random-effects hazard ratio 1.80, 95%CI 1.62-2.0; *I2*=89%). This risk further increased across the severity of MASLD, especially the severity of fibrosis (pooled random-effects hazard ratio 2.42, 95%CI 1.89-2.29; *I2*=92%). These results remained significant after adjusting for age, sex, obesity, diabetes, and other potential confounders. Sensitivity analyses did not modify these findings. The funnel plot did not reveal any significant publication bias.

**Conclusions**: This meta-analysis shows a significant association between MASLD and an increased risk of serious bacterial infections requiring hospital admission.

**Keywords**: Non-alcoholic fatty liver disease; NAFLD; metabolic dysfunction-associated steatotic liver disease; MASLD; serious bacterial infections; meta-analysis

**LAY SUMMARY**

This comprehensive meta-analysis of observational studies shows for the first time that MASLD is significantly associated with an increased risk of having or developing serious bacterial infections requiring hospital admission. Further well-designed prospective and mechanistic studies are needed to better understand the link between MASLD and the risk of developing serious bacterial infections.

**LIST OF ABBREVIATIONS**

MASLD, metabolic dysfunction-associated steatotic liver disease

MASH, metabolic dysfunction-associated steatohepatitis

MDR, multidrug resistant

NAFLD, nonalcoholic fatty liver disease

NOS, Newcastle-Ottawa scale

HR, hazard ratio

OR, odds ratio

**INTRODUCTION**

Nonalcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated steatotic liver disease (MASLD), has become the leading cause of chronic liver disease globally. The recent nomenclature change from NAFLD to MASLD responds to our better understanding of the pathophysiological processes that lead to the development and progression of MASLD (where metabolic dysfunction plays a pathogenic role in the pathophysiology of this common liver disease (1). The worldwide prevalence of MASLD is estimated to be around 38% among adult individuals and is projected to continue to rise with increasing global rates of obesity and type 2 diabetes (1-3).

MASLD poses a significant health and economic burden worldwide (4, 5). Substantial epidemiological evidence indicates that MASLD is a multisystem disease (6, 7) that is associated not only with liver-related complications (cirrhosis, end-stage liver disease and hepatocellular carcinoma) but also with an increased risk of developing extrahepatic cancers (mainly gastrointestinal cancers) (8) and cardiometabolic comorbidities, such as new-onset type 2 diabetes mellitus (9), fatal and nonfatal cardiovascular events (10), and adverse renal outcomes (11).

Among the least investigated MASLD-related extrahepatic complications, an ever-increasing number of observational cross-sectional and prospective studies have assessed the association between MASLD and the risk of serious bacterial infections, such as pneumonia, meningitis, sepsis, gastrointestinal/abdominal infections or other bacterial infections requiring hospital admission (as extensively discussed below). However, the magnitude of this risk and whether the risk varies with the severity of MASLD remains uncertain.

Therefore, we have performed a comprehensive systematic review and meta-analysis of relevant observational studies to quantify the magnitude of the association between MASLD and the risk of serious bacterial infections requiring hospital admission. Moreover, we have also examined whether there was an association between the severity of MASLD and the risk of serious bacterial infections. Clarifying the magnitude of the risk of serious bacterial infections requiring hospital admission in patients with MASLD might favor the development of prevention strategies for serious bacterial infections in this patient population.

**MATERIALS AND METHODS**

*Registration of review protocol*

The protocol of this systematic review was registered on Open Science Framework (registration DOI: https://doi.org/10.17605/OSF.IO/B7TDG).

*Data sources and searches*

This systematic review has been performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and the Meta-analysis Of Observational Studies in Epidemiology (MOSE) guidelines (11, 12). We systematically searched PubMed, Web of Science, Embase, and Scopus from database inception to April 1, 2024, to identify relevant observational studies examining the association between MASLD and the risk of serious bacterial infections requiring hospital admission. Search free text terms were "serious bacterial infections" OR “severe bacterial infections” OR "serious/severe infections" OR "bacterial infections" OR “infectious diseases” AND “fatty liver” OR “nonalcoholic fatty liver disease” OR “NAFLD” OR “nonalcoholic steatohepatitis” OR “NASH” OR “metabolic dysfunction-associated steatotic liver disease” OR “MASLD” OR “metabolic dysfunction-associated steatohepatitis” OR “MASH”. Searches were restricted to human studies and English language studies. Subjects included in the meta-analysis were of either sex without age, race, or ethnicity restrictions.

*Study selection*

The inclusion criteria of the meta-analysis were as follows: 1) observational (cross-sectional, case-control, or longitudinal) studies examining the risk of serious bacterial infections requiring hospital admission amongst adult (age ≥18 years) individuals with and without MASLD (or NAFLD); 2) studies that reported odds ratios (ORs) or hazard ratios (HRs) with 95% confidence intervals (95% CIs) values for the outcome of interest; 3) the diagnosis of MASLD (or NAFLD) was based on liver biopsy, imaging techniques, blood-based biomarkers/scores or International Classification of Diseases (ICD) codes, in the absence of significant alcohol consumption (usually defined as <20 g/day for women and <30 g/day for men) or other competing causes of hepatic steatosis (e.g., viral hepatitis, iron overload and use of potentially hepatotoxic drugs); and 4) the diagnosis of serious bacterial infections, such as pneumonia, meningitis, sepsis, gastrointestinal/abdominal infections or other severe bacterial infections requiring hospital admission was based on hospital charts, electronic medical records or ICD-9/ICD-10 codes (as specified in each eligible study).

The exclusion criteria of the meta-analysis were as follows: 1) congress abstracts, case reports, reviews, practice guidelines or commentaries; 2) studies in which the identification of MASLD (or NAFLD) was based exclusively on serum aminotransferase concentrations; 3) studies which did not exclude individuals with significant alcohol consumption or other known causes of chronic liver disease; 4) studies that examined the association between MASLD (or NAFLD) and the risk of non-severe bacterial infections (e.g., prior or active *Helicobacter pylori* infection or periodontitis); and 5) studies that examined the associations between MASLD (or NAFLD) and the risk of more severe COVID-19 infection or other types of infections (viral, fungal or parasitic).

*Data extraction and quality assessment*

Data from studies eligible for the aggregate data meta-analysis were independently extracted by two investigators (AM and GT). Any disagreements between investigators about including eligible studies were resolved by consensus and a third investigator if needed (RM).

For each eligible study, we extracted data on publication year, study design, sample size, country, population characteristics, methodologies used for the diagnosis of MASLD and serious bacterial infections, severity of MASLD, outcomes of interest, matching and confounding factors included in multivariable regression analyses, and length of follow-up (for longitudinal studies). In the case of multiple publications of the same database, we included the most up-to-date or comprehensive information.

The overall quality of the studies included in the aggregate data meta-analysis was assessed using the Newcastle-Ottawa scale (NOS) by two independent authors (AM and GT). Any disparities in scoring were reviewed, and consensus was obtained following discussion. The NOS scale is a validated scale for non-randomized studies in meta-analyses, which uses a star system to assess the quality of a study in three domains: selection, comparability, and outcome/exposure. The NOS assigns a maximum of four stars for selection (or five stars in the case of cross-sectional studies), two for comparability, and three for outcome/exposure. We judged studies that received a score of at least eight stars to be at low risk of bias, thus reflecting the highest quality.

*Data synthesis and analysis*

The primary outcome measure of the meta-analysis was the presence of serious bacterial infections, such as pneumonia, meningitis, sepsis, urinary tract infections, gastrointestinal/abdominal infections or other bacterial infections requiring hospital admission for cross-sectional studies or the risk of developing incident serious bacterial infections requiring hospital admission over the follow-up for longitudinal studies. The ORs (for cross-sectional studies) or HRs (for longitudinal studies) and their 95% CIs were considered as the effect size for all the eligible studies. When studies reported ORs/HRs with varying degrees of covariate adjustment, we extracted those that reflected the maximum extent of adjustment for potentially confounding factors. The adjusted ORs/HRs of all eligible studies were pooled, and an overall effect-size estimate was calculated using a random-effects model since high heterogeneity was expected for a meta-analysis of observational studies.

The statistical heterogeneity among studies was evaluated by the chi-square test and the *I2*-statistic, which estimates the percentage of variability across studies due to heterogeneity rather than chance alone. The proportion of heterogeneity accounted for by between-study variability was assessed using the *I2*-statistic and adjudicated to be significant if the *I2* index was >50% (13). The possibility of publication bias was examined using the visual inspection of funnel plots and the Egger’s regression asymmetry test (14).

To explore the possible sources of (expected) high heterogeneity among the included studies and test the robustness of the observed associations, we performed subgroup analyses by study country, study design, and diagnostic methods used for identifying MASLD. We also tested for possible excessive influence of individual studies using a meta-analysis influence test that eliminated each included study at a time. Finally, we performed univariable meta-regression analyses to test the impact of age, sex, body mass index (BMI) and percentage of established diabetes on the effect size for the association between MASLD and the risk of serious bacterial infections.

All statistical tests were two-sided and a *p-*value<0.05 was considered significant. We used R version 4.3.3 (R Core Team 2023, R Foundation for Statistical Computing, Vienna, Austria. <https://www.R-project.org/>) for all statistical analyses with the following packages: *meta* (version 7.0-0) and *metafor* (version 4.4-0).

**RESULTS**

*Study selection and characteristics*

The PRISMA flow diagram summarizes the search and selection processes of the meta-analysis (**Supplementary Figure 1**). After examining the titles and abstracts of the publications and excluding duplicates, we identified 12 potentially eligible studies from four large electronic databases (PubMed, Scopus, Embase and Web of Science) from the inception to April 1, 2024. We excluded four observational studies because of unsatisfactory outcome measures (as specified in **Supplementary Table** **1**). Consequently, we identified eight unique observational studies (six cross-sectional and two prospective studies) for the final inclusion in the meta-analysis.

The main characteristics of these selected observational studies are shown in **Table 1** (15-22). Overall, the six cross-sectional hospital-based studies included 26,434,377 individuals hospitalized for serious bacterial infections (43.6% men; mean age 60 years; ~36% had a diagnosis of MASLD). The diagnosis of MASLD was based on liver ultrasonography and/or computed tomography (n=5 studies) and ICD-10 codes (n=1 study). No cross-sectional studies were available on using liver biopsy to diagnose MASLD. Four studies were conducted in Israel, one in the USA, and one in Croatia. Four of these six studies obtained 7 stars and two studies obtained 6 stars on the NOS scale, thus reflecting a moderately high risk of bias. As shown in **Table 1**, the two eligible prospective cohort studies were carried out in Sweden and included 221,663 adult individuals (52% men; mean age 55 years) followed for a median period of 14.1 and 5.3 years, respectively. The diagnosis of MASLD was based on liver biopsy in one cohort study and ICD codes in the other. The two cohort studies obtained at least 7 stars on the NOS scale, thus reflecting a relatively low risk of bias.

*Cross-sectional studies on the association between MASLD and serious bacterial infections*

The distribution of cross-sectional studies (involving 26,434,377 adult individuals from different countries) by estimate of the association between MASLD and the risk of serious bacterial infections requiring hospital admission is plotted in **Figure 1** (15-20). We found thatMASLD was significantly associated with higher odds of serious bacterial infections (n=6 studies; pooled random-effects odds ratio 1.93, 95%CI 1.44-2.58; *I2*=93%). The serious bacterial infections requiring hospital admission considered in each eligible study are reported in **Table 1**. Since we have always used the fully adjusted OR estimates for each eligible study, this pooled random-effects OR was independent of age, sex, ethnicity, obesity, diabetes and other potential confounders (as specified in **Table 1**).

*Longitudinal studies on the association between MASLD and the risk of developing serious bacterial infections*

The distribution of prospective studies (n=2 nationwide cohort studies including 221,663 Swedish individuals) by estimate of the association between MASLD and the risk of incident serious bacterial infections requiring hospital admission is plotted in **Figure 1**. MASLD assessed by liver biopsy or ICD codes was significantly associated with a higher risk of developing serious bacterial infections requiring hospital admission (pooled random-effects hazard ratio 1.80, 95%CI 1.62-2.0; *I2*=89%). This risk was independent of age, sex, county, education level and multiple baseline clinical comorbidities (including diabetes, obesity, dyslipidemia, hypertension, or chronic obstructive pulmonary disease).

*Longitudinal studies on the association between the severity of MASLD and the risk of developing serious bacterial infections*

The distribution of prospective cohort studies by estimate of the association between the severity of MASLD and the risk of developing serious bacterial infections is plotted in **Figure 2**. Incidence rates of serious bacterial infections requiring hospital admission were further increased with more advanced liver disease, especially with higher fibrosis stage, i.e., noncirrhotic fibrosis or cirrhosis (n=2 studies; pooled random-effects hazard ratio 2.42, 95%CI 1.89-2.29; *I2*=92%). The ICD-9/ICD-10 codes used for diagnosing all subtypes of serious bacterial infections in each cohort study are specified in **Supplementary Document 1 and 2** in the online-only Supplementary Material.

*Subgroup analyses and meta-regressions in cross-sectional studies*

We undertook subgroup analyses to explore the possible sources of (expected) high heterogeneity across the cross-sectional studies. As shown in **Supplementary Figure 2**,the association between MASLD and the odds of serious bacterial infections requiring hospital admission was consistent when the comparison was stratified by study design (case-control vs. cross-sectional studies). Conversely, the association between MASLD and serious bacterial infections was more robust in Israeli and Croatian studies than in the USA study (**Supplementary Figure 3**), as well as in studies where the diagnosis of MASLD was based on imaging techniques than in those using ICD codes (**Supplementary Figure 4**).

Notably, a sensitivity analysis using the one-study remove (leave-one-out) approach to test the influence of each study on the overall effect size showed that eliminating each of the cross-sectional studies from the pooled primary analysis did not show any significant effect on the association between MASLD and risk of serious bacterial infections (**Supplementary Figure 5**). Univariable meta-regression analyses did not reveal any effect modification by age (**Supplementary Figure 6**), sex (**Supplementary Figure 7**), body mass index (**Supplementary Figure 8**), and pre-existing diabetes (**Supplementary Figure 9**) on the association between MASLD and the risk of serious infections.

*Publication bias*

As shown in **Figure 3**, the visual inspection and the Egger’s regression test (although less than ten studies were included) did not show any statistically significant asymmetry of the funnel plot for the included studies (p=0.336), thus suggesting that the publication bias was low.

**DISCUSSION**

In this comprehensive systematic review and meta-analysis that incorporated eight observational studies (six cross-sectional hospital-based studies and two population-based cohort studies) with aggregate data on ~26.6 million adult individuals from different countries (Israel, Croatia, Sweden and the USA), we found that MASLD was significantly associated with a ~twofold higher prevalence of serious bacterial infections that required in-hospital or emergency department care (n=6 studies; pooled random-effects odds ratio 1.93, 95%CI 1.44-2.58). The association between MASLD and the risk of having serious bacterial infections requiring hospital admission remained significant in those studies where statistical analysis was adjusted for age, sex, ethnicity, obesity, type 2 diabetes, and other clinical comorbidities (as specified in **Table 1**). Meta-regression analyses did not show effect modification by age, sex, obesity or type 2 diabetes on the association between MASLD and the risk of having serious bacterial infections. Furthermore, this association was more robust in studies where the diagnosis of MASLD was based on imaging techniques than in those using ICD codes. Meta-analysis of data from the two population-based cohort studies showed that MASLD assessed by liver biopsy or ICD codes was significantly associated with a ~twofold higher incidence of serious bacterial infections requiring hospital admission (pooled random-effects hazard ratio 1.80, 95%CI 1.62-2.0), independent of age, sex, obesity, diabetes, and other baseline clinical comorbidities. Notably, the incidence rates of serious bacterial infections were further increased with more advanced liver disease, especially with higher fibrosis stage (pooled random-effects hazard ratio 2.42, 95%CI 1.89-2.29).

This is the first and most comprehensive meta-analysis of observational studies examining the magnitude of the association between MASLD and the risk of having or developing serious bacterial infections requiring hospital admission. Concordant with the overall results on serious bacterial infections, all subtypes of bacterial infection showed a higher risk in patients with MASLD than in those without. As reported in **Table 1**, MASLD was significantly associated with a higher prevalence and incidence of serious bacterial infections, especially urinary tract infections, upper or lower respiratory tract infections, and gastrointestinal/abdominal infections, followed by sepsis, meningitis, peritonitis, and musculoskeletal, skin or connective tissue infections. There was a graded relationship between the severity of MASLD and the increased risk of developing serious bacterial infections requiring hospital admission (with the highest risk observed for patients with advanced liver fibrosis or cirrhosis) (21, 22). Specifically, in the Swedish nationwide cohort study by Ebrahimi et al. (21), the risk of developing serious bacterial infections increased progressively and independently with worsening MASLD histological severity over a median of 14.1 years (isolated hepatic steatosis (adjusted HR 1.64, 95% CI 1.55-1.73), nonfibrotic steatohepatitis [adjusted HR 1.84, 95% CI 1.60-2.12], noncirrhotic fibrosis [aHR 1.77, 95% CI 1.56-2.0], and cirrhosis [adjusted HR 2.32, 95% CI 1.92-2.82]). Similarly, in the Swedish cohort study by Shang et al. (22), both noncirrhotic MASLD (adjusted HR 1.90, 95% CI 1.7-2.0) and MASLD without diabetes (adjusted HR 1.90, 95% CI 1.8-2.1) were independently associated with higher risk of developing serious bacterial infections, although this risk was stronger for MASLD-related cirrhosis (adjusted HR 3.60, 95% CI 2.7-4.6). In this latter cohort study (22), MASLD was also independently associated with a greater risk of infection-related mortality (adjusted HR 1.80, 95% CI 1.6-2.2). Based on subgroup analyses, these investigators also reported that attention should be paid to young and female patients with MASLD, whose liver disease may have a comparatively stronger adverse impact on the incidence of serious bacterial infections (22). The findings of our meta-analysis complement the results of previously published meta-analyses showing that MASLD was also associated with an increased risk of *Helicobacter pylori* infection and more severe COVID-19 infection (23, 24).

The findings of this meta-analysis may have some important clinical implications. Our results apply to serious bacterial infections requiring in-hospital or emergency department care and, therefore, cannot be extrapolated to milder bacterial infections. That said, clinicians need to be aware of the increased risk in most, if not all, types of bacterial infections among patients with MASLD (especially among those with advanced fibrosis or cirrhosis) and should also have increased clinical vigilance for serious bacterial infections and consider preventive measures, such as regular checks of vaccination status (21, 22). Patients should be advised to seek medical attention in case of acute infections. With an approximately twofold increase in the risk of serious bacterial infections and infection-related death, patients with MASLD should receive broad-spectrum antibiotics if hospitalized for bacterial infection, with the choice of antibiotic therapy refined when culture test results become available (25). Furthermore, given the greater risk of colonization by multidrug-resistant bacteria (MDR bacteria) in patients with liver failure, it could also be helpful to perform rectal and nasal swabs for MDR bacteria in the presence of serious infection. Future studies should examine whether drug treatment of MASLD will reduce the incidence rates of serious bacterial infections in this patient population. Although not specifically tested in the present meta-analysis, it is reasonable to assume that patients with MASLD, especially those without advanced MASLD or with coexisting diabetes/obesity, are also at increased risk of developing viral, fungal, and parasitic infections. This implies that clinicians need to be aware that the risk of infectious diseases is high in this patient population and should be monitored especially in those with more advanced MASLD (MASLD-related cirrhosis) and those who have coexisting type 2 diabetes or obesity.

A detailed discussion of the putative mechanisms underpinning the association between MASLD and the risk of serious bacterial infections (e.g., pneumonia, meningitis, urinary tract infections, gastrointestinal/abdominal infections, peritonitis and sepsis) is beyond the scope of the meta-analysis. Briefly, the liver is essential for host defense against infectious diseases. Bacterial infections are common among patients with cirrhosis (including spontaneous bacterial peritonitis) and may result in hepatic decompensation and liver-related mortality (26). MASLD is closely associated with obesity and type 2 diabetes. Whilst these are two metabolic diseases known to increase the susceptibility to bacterial infections, neither obesity nor pre-existing type 2 diabetes modified the strength of the association in univariable meta-regression analyses we undertook. Other factors, such as systemic low-grade chronic inflammation, impaired immune system function and intestinal dysbiosis, may also increase the susceptibility to bacterial infections in patients with MASLD (25, 27). Accumulating research supports a role of intestinal barrier disruption and bacterial translocation from leaky gut in MASLD as an important contributing to the development of bacterial infections and other types of infections (viral, fungal or parasitic), both at the intestinal and extra-intestinal level (28). However, the precise mechanisms and the interplay of the mentioned factors remain not fully understood. Further mechanistic studies are needed to better elucidate these issues.

Our meta-analysis has some important limitations, which are inherent to the design of the included studies. First, since most of the included studies had a retrospective cross-sectional design, we cannot establish a causal association between MASLD and serious bacterial infections requiring hospital admission. Second, although most eligible studies adjusted the results for age, sex, ethnicity, obesity, diabetes and other clinical comorbidities, the possibility of residual confounding by unmeasured factors cannot be entirely excluded. For instance, although the diagnosis of MASLD requires the exclusion of significant alcohol consumption, alcohol consumption is often under-reported in individuals classified as having MASLD (thus inducing a possible misclassification bias) and alcohol and metabolic factors may interact to exacerbate the progression of liver disease and the risk of developing bacterial infections (29). Third, although we used a random-effects model, the interpretation of some results requires some caution because of the observed medium-high heterogeneity for the pooled primary analysis of cross-sectional studies and the moderate overall quality of the studies, suggesting a medium-high risk of bias according to the NOS. Detailed subgroup analyses by types of serious bacterial infection (that could partly explain the observed high between-study heterogeneity) cannot be performed. Fourth, although all eligible studies have used the NAFLD nomenclature, for this meta-analysis, we have assumed that NAFLD and MASLD are synonymous, as the two fatty liver disease nomenclatures share a very high level of overlap (>96% of individuals with NAFLD meet the diagnostic criteria for MASLD) (30-32). Fifth, an assessment of the severity of liver fibrosis (using non-invasive fibrosis biomarkers/scores) was not available for the eligible cross-sectional studies; it was only available for the two prospective cohort studies. Sixth, although a selective reporting bias of eligible studies could not be excluded, our comprehensive search has made it unlikely that any published studies were missed. Sixth, although in one large cross-sectional study by Patel et al. the diagnosis of NAFLD was based on ICD codes (so the liver disease could be underdiagnosed), it should be noted that the one-study remove (leave-one-out) approach to test the influence of each study on the overall effect size showed that eliminating of the study by Patel et al. (Supplementary Fig. 5) from the pooled analysis increased the magnitude of the association between MASLD and risk of serious bacterial infections (pooled random-effects odds ratio 2.11, 95%CI 1.55-2.88). Finally, these results derived from studies from high-income countries may not be directly transferable to low-income countries (where the risk of severe bacterial infections is higher) because poor communities were largely underrepresented in the meta-analysis. Further prospective cohort studies will be needed in low and lower-middle-income countries (33).

Despite these limitations, the present meta-analysis also has important strengths. Our meta-analysis is the first and largest assessment of the association between MASLD and the risk of serious bacterial infections requiring hospital admission. The large number of individuals included in the meta-analysis (although the limited number of observational studies available so far) provided sufficient statistical power to quantify the magnitude of the association between MASLD and the risk of serious bacterial infections. Moreover, we have used standardized risk estimates from all included studies to allow a consistent combination of estimates across eligible studies. Finally, the visual inspection of the funnel plot did not reveal any significant asymmetry, thus suggesting that the risk of publication bias was low.

In conclusion, this comprehensive meta-analysis provides evidence of a significant association between MASLD and an increased risk of developing serious bacterial infections requiring hospital admission (such as pneumonia, meningitis, urinary tract infections, gastrointestinal/abdominal infections, or sepsis). This association remained statistically significant in those studies whose results were adjusted for age, sex, ethnicity, obesity, type 2 diabetes and other important clinical comorbidities. Incidence rates of serious bacterial infections requiring hospital admission increased further with greater severity of MASLD, principally higher fibrosis stage. Future well-designed large prospective studies from different countries (including Asian populations and low-income countries) are needed to further corroborate these results, and mechanistic studies are also required to better decipher the complex molecular pathways linking MASLD with increased susceptibility to developing serious bacterial infections requiring hospital admission.

**Conflicts of interest statement:** The Authors have no potential conflicts of interest to disclose.

**Funding Statement:** There was no funding source for this specific study. GT is supported in part by grants from the University School of Medicine of Verona, Verona, Italy. CDB is supported in part by the Southampton NIHR Biomedical Research Centre (NIHR203319), UK. This study was partly supported by the Italian Ministry of Health under Fondi Ricerca Corrente — Linea 1 (IRCCS Sacro Cuore - Don Calabria Hospital).

**Author Contributions:** All listed authors contributed greatly to this study and fulfilled the stated guidelines for authorship, as described by the published criteria for authorship by the ICMJE. Each author participated sufficiently in the work to take public responsibility for appropriate portions of the content. Below is a detailed account of each author’s contribution: AM and GT were involved in the conception of the study and the analysis and interpretation of the results. GT wrote the first draft of the manuscript. RM, VF and MGL were involved in the conduct of the study and searched the published articles. AG, LM, FG, HT and CDB were involved in the interpretation of the results and contributed to the discussion. All authors edited, reviewed, and approved the final version of the manuscript.

**Data availability statement**: All supporting data of the meta-analysis are available within the article and in the online-only Supplementary Material.

**Research Ethics Approval**: This study involves human participants but was not approved by an Ethics Committee. Approval from an Ethics Committee is not necessary as this is a meta-analysis of published observational studies that had already obtained both informed consent from participants and ethical approval by their local Ethics committees.

**Table 1**. Eligible cross-sectional (n=6) and prospective studies (n=2) examining the association between MASLD and the risk of having or developing serious bacterial infections requiring hospital admission.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Authors, Year (ref.)** | **Study**  **design** | **Study**  **participants** | **MASLD diagnosis, % of cases\*** | **Outcome measure, % of cases** | **Covariate adjustments** | **Study results** | **NOS** |
| ***Cross-sectional studies*** | | | | | | | |
| Nseir W et al., 2011 (15) | Cross-sectional hospital-based study (retrospective analysis) | 347 Israeli hospitalized adult individuals (M/F: 159/188, mean age: 52 years, mean BMI: 29.5 kg/m2, % diabetes: 38%) | Ultrasound,  70% (n=247) | Recurrent bacterial infections over 3 years (urinary tract infections, upper  or lower respiratory tract infections or soft tissue infections), 17.6% (n=61) | Age, obesity, diabetes, metabolic syndrome, waist circumference, HOMA-IR, serum C-reactive protein, serum MDA, serum ALT, serum PON-1 activity, and serum 25(OH)D levels | MASLD was associated with higher risk of recurrent bacterial infections, especially urinary tract infections (aOR 3.0, 95% CI 2.6-4.2) | 7 |
| Nseir W et al., 2017 (16) | Hospital-based case-control study (retrospective analysis) | 141 Israeli hospitalized adult individuals with community-acquired pneumonia  and 141 hospitalized individuals without community-acquired pneumonia  matched for age, sex, and BMI (M/F: 180/102, mean age: 63 years, mean BMI: 30 kg/m2, % diabetes: 50%) | Ultrasound or computed tomography,  34% (n=96) | Community-acquired pneumonia, 50% (n=141) | Age, sex, BMI, smoking history, diabetes, congestive heart failure, and chronic obstructive pulmonary disease | MASLD was associated with higher risk of community-acquired pneumonia  (aOR 2.50, 95% CI 2.0-3.15) | 7 |
| Nseir W et al., 2019 (17) | Hospital-based case-control study (retrospective analysis) | 186 Israeli hospitalized premenopausal women with acute urinary tract infections and sepsis  and 186 premenopausal women without acute urinary tract infections or sepsis matched for age, sex, and BMI (M/F: 0/372, mean age: 40 years, mean BMI: 30.5 kg/m2, % diabetes: NA) | Ultrasound,  32.5% (n=121) | Recurrent urinary tract infections over 3 years,  50% (n=186) | Age, obesity, maternal history of recurrent urinary tract infections, no-use of probiotics, sexual intercourse, and serum 25(OH)D levels | MASLD was associated with higher risk of recurrent urinary tract infections (aOR 1.60, 95% CI 1.3-2.0) in premenopausal women | 7 |
| Nseir W et al., 2020 (18) | Hospital-based case-control study (retrospective analysis) | 115 Israeli hospitalized adult individuals with Clostridium difficile-associated diarrhea  and 115 hospitalized individuals without Clostridium difficile-associated diarrhea matched for age, sex and BMI (M/F: 134/96, mean age: 68.5 years, mean BMI: 26.3 kg/m2, % diabetes: 42.6%) | Ultrasound or computed tomography,  48.3% (n=111) | Clostridium difficile-associated diarrhea over 4 years, 50% (n=115) | Age, metabolic syndrome, chronic kidney disease, prior antibiotic use in the last 3 months, and elevated serum C reactive protein levels | MASLD was associated with higher risk of Clostridium difficile-associated diarrhea (aOR ratio 1.51, 95% CI 1.20-1.85) | 6 |
| Papic N et al., 2020 (19) | Cross-sectional hospital-based study (retrospective analysis) | 314 Croatian hospitalized adult individuals for various acute infections or sepsis (M/F: 170/144, mean age: 75 years, mean BMI: NA, % obesity: 11%, % diabetes: 28%) | Ultrasound,  26.4% (n=83) | In-hospital Clostridium difficile-associated diarrhea over 3 years, 9.9% (n=31) | Charlson age-comorbidity index, hospital admission within 3 months, low serum albumin, chronic kidney disease (eGFR <40 ml/min), obesity, diabetes, and use of certain antibiotics (piperacillin/tazobactam or carbapenems) | MASLD was associated with higher risk of Clostridium difficile-associated diarrhea (aOR ratio 3.27 95% CI 1.04-10.3) | 7 |
| Patel J et al., 2024 (20) | Cross-sectional population-based study using data from the National Inpatient  Sample (NIS), the largest all-payer USA in-patient care database (retrospective analysis) | ~26.4 million Unites States adult patients admitted to hospitals in 2020 (n=26,432,832)  (M/F:11,513,311/14,919,521, age >65 years: 46%, >65% Caucasian, % obesity: 18.7%, % diabetes: 28.5%) | ICD-10 codes,  3.0% (n=755,910) | Acute gastrointestinal infections (as ascertained by ICD-10 codes), 0.92% (n=243,255)  Specific rates of Clostridium difficile, Escherichia  coli, and Salmonella were also examined | Age, sex, race, household income, income, Charlson comorbidity index, obesity, diabetes, hypertension, smoking history, dyslipidemia, obstructive sleep apnea, gastro-esophageal  reflux disease, and inflammatory bowel disease | MASLD was associated with higher risk of acute bacterial gastrointestinal infections (aOR 1.36, 95% CI 1.30-1.42) (principally higher infection rates from Clostridium difficile, Escherichia  coli, and Salmonella) | 6 |
| ***Prospective studies*** | | | | | | | |
| Ebrahimi F et al., 2023 (21) | Nationwide population-based cohort study (retrospective analysis) | Swedish adults with histologically confirmed MASLD (n=12,133) from 1969 to 2017. Patients were matched to ≤5 population comparators (n=57,516) by age, sex, calendar year, and county (M/F 37,771/31,878, mean age 54 years, % obesity: 1.1%, % diabetes: 3%). Median follow-up of 14.1 years | Liver biopsy, 17.5% (n=12,133).  NAFLD was defined as simple steatosis (n=8,232), nonfibrotic steatohepatitis (n=1,378), noncirrhotic fibrosis (n=1,845), and cirrhosis (n=678) | n=19,572 cases hospitalized for serious bacterial infections over the follow-up (especially acute respiratory, urinary tract infections and sepsis) (as ascertained by ICD-9/ICD-10 codes)§ | Age, sex, county, calendar period, education level, country of birth, baseline clinical comorbidities (diabetes, obesity, dyslipidemia, hypertension), chronic obstructive pulmonary disease, and number of  hospitalizations in the year preceding the index date | MASLD was associated with higher risk of developing serious bacterial infections (aHR, 1.71, 95% CI 1.63-1.79). Risk of serious infections increased with worsening histological severity of NAFLD (simple steatosis [aHR 1.64, 95% CI 1.55–1.73], nonfibrotic steatohepatitis [aHR 1.84, 95% CI 1.60–2.12], noncirrhotic fibrosis [aHR 1.77, 95% CI 1.56–2.00], and cirrhosis [aHR 2.32, 95% CI,1.92–2.82]), respectively | 8 |
| Shang Y et al., 2023 (22) | Nationwide population-based cohort study (retrospective analysis) | Swedish adult patients with MASLD (n=14,869) from 1987 to 2020 in the Swedish National Patient Register. Patients were matched to ≤10 population comparators (n=137,145) by age, sex, municipality, and calendar year (M/F 77,276/74,738, mean age 55 years, % obesity 3.5%, diabetes: 5.7%). Median follow-up of 5.3 years | ICD codes, 9.8% (n=14,869) | n=11,889 cases hospitalized for serious infections over the follow-up (especially acute respiratory and urogenital infections, sepsis followed by gastrointestinal infections, peritonitis and musculoskeletal or skin infections) (as ascertained by ICD-9/ICD-10 codes)§ | Age, sex, municipality, calendar year, country of birth, education level, chronic obstructive pulmonary disease, cancer, rheumatic disease, inflammatory bowel disease, dementia, cardiovascular disease, diabetes, obesity, and chronic kidney disease | MASLD was associated with higher risk of developing serious infections (aHR, 1.90, 95% CI 1.8-2.0). Moreover, MASLD was also associated with higher risk of death related to infections (aHR, 1.80, 95% CI 1.6-2.2).  Notably, both non-cirrhotic  NAFLD (aHR 1.9, 95%  CI 1.7–2.0)  and NAFLD without diabetes (aHR 1.9, 95% CI 1.8-2.1)  were associated with higher risk of serious infections, although this risk was stronger for NAFLD- cirrhosis (aHR 3.6, 95% CI 2.7-4.6). Concordant with the overall results on serious infection,  all subtypes of serious infection showed a higher risk  in patients with MASLD | 7 |

\*Originally labelled as NAFLD. §The specific ICD-9/ICD-10 codes used for diagnosing all subtypes of serious bacterial infections in each prospective cohort study were reported in **Supplementary Document 1 and 2 in our online-only Supplementary Material**.

*Abbreviations*: NA, not available; aOR, adjusted odds ratio; aHR, adjusted hazard ratio; ALT, alanine aminotransferase; BMI, body mass index; HOMA-IR, homeostasis model assessment-insulin resistance; MDA, malondialdehyde; PON-1; paraoxonase-1; 25(OH)D, 25 hydroxyvitamin D.

**FIGURE LEGENDS**

**Figure 1**. Forest plot and pooled estimates of the effect of MASLD on the risk of serious bacterial infections requiring hospital admission in the eligible studies stratified by study design (cross-sectional vs. prospective studies).

**Figure 2**. Forest plot and pooled estimates of the effect of more serious MASLD (i.e., advanced fibrosis or cirrhosis) on the risk of developing incident serious bacterial infections requiring hospital admission in the eligible prospective studies.

**Figure 3**. Funnel plot assessing the possibility of publication bias across the eligible studies (n=8).

**REFERENCES**

1. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542-56. Epub 2023/06/27. doi: 10.1016/j.jhep.2023.06.003. PubMed PMID: 37364790.

2. Miao L, Targher G, Byrne CD, Cao YY, Zheng MH. Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab. 2024. Epub 2024/03/02. doi: 10.1016/j.tem.2024.02.007. PubMed PMID: 38429161.

3. Wong VW, Ekstedt M, Wong GL, Hagstrom H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol. 2023;79(3):842-52. Epub 2023/05/12. doi: 10.1016/j.jhep.2023.04.036. PubMed PMID: 37169151.

4. Paik JM, Henry L, Younossi Y, Ong J, Alqahtani S, Younossi ZM. The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019. Hepatol Commun. 2023;7(10). Epub 2023/10/02. doi: 10.1097/HC9.0000000000000251. PubMed PMID: 37782469; PubMed Central PMCID: PMCPMC10545420 Squibb, GENFIT, Gilead, Intercept, Madrigal, Merck, Novo Nordisk, Siemens, Terns, and Viking. The remaining authors have no conflicts to report.

5. Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism. 2020;111S:154170. Epub 2020/02/02. doi: 10.1016/j.metabol.2020.154170. PubMed PMID: 32006558.

6. Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol. 2021;6(7):578-88. Epub 2021/05/08. doi: 10.1016/S2468-1253(21)00020-0. PubMed PMID: 33961787.

7. Zhao J, Liu L, Cao YY, Gao X, Targher G, Byrne CD, et al. MAFLD as part of systemic metabolic dysregulation. Hepatol Int. 2024. Epub 2024/04/10. doi: 10.1007/s12072-024-10660-y. PubMed PMID: 38594474.

8. Mantovani A, Petracca G, Beatrice G, Csermely A, Tilg H, Byrne CD, et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut. 2022;71(4):778-88. Epub 2021/03/10. doi: 10.1136/gutjnl-2021-324191. PubMed PMID: 33685968.

9. Mantovani A, Petracca G, Beatrice G, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut. 2021;70(5):962-9. Epub 2020/09/18. doi: 10.1136/gutjnl-2020-322572. PubMed PMID: 32938692.

10. Mantovani A, Csermely A, Petracca G, Beatrice G, Corey KE, Simon TG, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(11):903-13. Epub 2021/09/24. doi: 10.1016/S2468-1253(21)00308-3. PubMed PMID: 34555346.

11. Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Schattenberg JM, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. 2022;71(1):156-62. Epub 2020/12/12. doi: 10.1136/gutjnl-2020-323082. PubMed PMID: 33303564.

12. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-12. Epub 2000/05/02. doi: 10.1001/jama.283.15.2008. PubMed PMID: 10789670.

13. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-58. Epub 2002/07/12. doi: 10.1002/sim.1186. PubMed PMID: 12111919.

14. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-34. Epub 1997/10/06. doi: 10.1136/bmj.315.7109.629. PubMed PMID: 9310563; PubMed Central PMCID: PMCPMC2127453.

15. Nseir W, Taha H, Khateeb J, Grosovski M, Assy N. Fatty liver is associated with recurrent bacterial infections independent of metabolic syndrome. Dig Dis Sci. 2011;56(11):3328-34. Epub 2011/05/13. doi: 10.1007/s10620-011-1736-5. PubMed PMID: 21562784.

16. Nseir W, Artul S, Abu Rajab S, Mograbi J, Nasralla N, Mahamid M. Association between non-alcoholic fatty liver disease and hospitalized patients with community-acquired pneumonia. Isr Med Assoc J. 2017;19(3):198. Epub 2017/05/01. PubMed PMID: 28457103.

17. Nseir W, Amara A, Farah R, Ahmad HS, Mograbi J, Mahamid M. Non-alcoholic Fatty Liver Disease is Associated with Recurrent Urinary Tract Infection in Premenopausal Women Independent of Metabolic Syndrome. Isr Med Assoc J. 2019;21(6):386-9. Epub 2019/07/08. PubMed PMID: 31280506.

18. Nseir WB, Hussein SHH, Farah R, Mahamid MN, Khatib HH, Mograbi JM, et al. Nonalcoholic fatty liver disease as a risk factor for Clostridium difficile-associated diarrhea. QJM. 2020;113(5):320-3. Epub 2019/11/07. doi: 10.1093/qjmed/hcz283. PubMed PMID: 31688897.

19. Papic N, Jelovcic F, Karlovic M, Maric LS, Vince A. Nonalcoholic fatty liver disease as a risk factor for Clostridioides difficile infection. Eur J Clin Microbiol Infect Dis. 2020;39(3):569-74. Epub 2019/11/30. doi: 10.1007/s10096-019-03759-w. PubMed PMID: 31782025.

20. Patel J, Sohal A, Bains K, Chaudhry H, Kohli I, Khanna T, et al. Association of metabolic dysfunction-associated fatty liver disease with gastrointestinal infections: insights from National Inpatient Sample Database. BMJ Open Gastroenterol. 2024;11(1). Epub 2024/01/19. doi: 10.1136/bmjgast-2023-001224. PubMed PMID: 38237944; PubMed Central PMCID: PMCPMC10870785.

21. Ebrahimi F, Simon TG, Hagstrom H, Soderling J, Wester A, Roelstraete B, et al. Risk of Severe Infection in Patients With Biopsy-proven Nonalcoholic Fatty Liver Disease - A Population-based Cohort Study. Clin Gastroenterol Hepatol. 2023;21(13):3346-55 e19. Epub 2023/05/29. doi: 10.1016/j.cgh.2023.05.013. PubMed PMID: 37245712.

22. Shang Y, Widman L, Ebrahimi F, Ludvigsson JF, Hagstrom H, Wester A. Risk of infections in non-alcoholic fatty liver disease: A nationwide population-based cohort study. Liver Int. 2023;43(10):2142-52. Epub 2023/07/21. doi: 10.1111/liv.15680. PubMed PMID: 37475642.

23. Mantovani A, Lando MG, Borella N, Scoccia E, Pecoraro B, Gobbi F, et al. Relationship between Helicobacter pylori infection and risk of metabolic dysfunction-associated steatotic liver disease: An updated meta-analysis. Liver Int. 2024. Epub 2024/04/03. doi: 10.1111/liv.15925. PubMed PMID: 38567962.

24. Wang Y, Wang Y, Duan G, Yang H. NAFLD was independently associated with severe COVID-19 among younger patients rather than older patients: A meta-analysis. J Hepatol. 2023;78(4):e136-e9. Epub 2022/10/30. doi: 10.1016/j.jhep.2022.10.009. PubMed PMID: 36309129; PubMed Central PMCID: PMCPMC9597581.

25. Wang MY, Wong VW, Yip TC. Risk of severe infection in patients with non-alcoholic fatty liver disease: Implication on clinical management. Liver Int. 2023;43(10):2057-9. Epub 2023/09/18. doi: 10.1111/liv.15696. PubMed PMID: 37718718.

26. de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Baveno VIIF. Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959-74. Epub 2022/02/06. doi: 10.1016/j.jhep.2021.12.022. PubMed PMID: 35120736.

27. Krznaric J, Vince A. The Role of Non-Alcoholic Fatty Liver Disease in Infections. Life (Basel). 2022;12(12). Epub 2022/12/24. doi: 10.3390/life12122052. PubMed PMID: 36556417; PubMed Central PMCID: PMCPMC9788238.

28. Benede-Ubieto R, Cubero FJ, Nevzorova YA. Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD). Gut Microbes. 2024;16(1):2331460. Epub 2024/03/21. doi: 10.1080/19490976.2024.2331460. PubMed PMID: 38512763; PubMed Central PMCID: PMCPMC10962615.

29. Diaz LA, Arab JP, Louvet A, Bataller R, Arrese M. The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2023;20(12):764-83. Epub 2023/08/16. doi: 10.1038/s41575-023-00822-y. PubMed PMID: 37582985.

30. Ciardullo S, Carbone M, Invernizzi P, Perseghin G. Exploring the landscape of steatotic liver disease in the general US population. Liver Int. 2023;43(11):2425-33. Epub 2023/08/18. doi: 10.1111/liv.15695. PubMed PMID: 37592856.

31. Hagstrom H, Vessby J, Ekstedt M, Shang Y. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol. 2024;80(2):e76-e7. Epub 2023/09/08. doi: 10.1016/j.jhep.2023.08.026. PubMed PMID: 37678723.

32. Younossi ZM, Paik JM, Stepanova M, Ong J, Alqahtani S, Henry L. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. J Hepatol. 2024. Epub 2024/01/30. doi: 10.1016/j.jhep.2024.01.014. PubMed PMID: 38286339.

33. Danpanichkul P, Suparan K, Dutta P, Kaeosri C, Sukphutanan B, Pang Y, et al. Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019. Metabolism. 2024;158:155958. Epub 2024/06/29. doi: 10.1016/j.metabol.2024.155958. PubMed PMID: 38942169.